

10/007,747

Human N-Methyl-D-Aspartate Receptor Subunits,  
Nucleic Acids Encoding Same and Uses Therefor

This application is a continuation-in-part of a <sup>div. of</sup> <sup>which is</sup> <sup>div. of</sup> <sup>Aug. 28, 2000,</sup> <sup>08/231,193</sup> <sup>filed Apr 20, 1999,</sup> <sup>which is a</sup> <sup>9-8-04</sup> United States Serial No. 08/052,449, filed April 20, 1993, <sup>div. of 09/648,797 file</sup> now pending.

The present invention relates to nucleic acids  
5 and receptor proteins encoded thereby. Invention nucleic  
acids encode novel human N-methyl-D-aspartate (NMDA)  
receptor subunits. The invention also relates to methods  
for making such receptor subunits and for using the  
receptor proteins in assays designed to identify and  
10 characterize compounds which affect the function of such  
receptors, e.g., agonists and antagonists of NMDA  
receptors.

BACKGROUND OF THE INVENTION

The amino acid L-glutamate is a major excitatory  
15 neurotransmitter in the mammalian central nervous system.  
Anatomical, biochemical and electrophysiological analyses  
suggest that glutamatergic systems are involved in a broad  
array of neuronal processes, including fast excitatory  
synaptic transmission, regulation of neurotransmitter  
20 releases, long-term potentiation, learning and memory,  
developmental synaptic plasticity, hypoxic-ischemic damage  
and neuronal cell death, epileptiform seizures, as well as  
the pathogenesis of several neurodegenerative disorders.  
See generally, Monaghan et al., Ann. Rev. Pharmacol.  
25 Toxicol. 29:365-402 (1980). This extensive repertoire of  
functions, especially those related to learning,  
neurotoxicity and neuropathology, has stimulated recent  
attempts to describe and define the mechanisms through  
which glutamate exerts its effects.

30 Currently, glutamate receptor classification  
schemes are based on pharmacological criteria. Glutamate